Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina.
Nifurtimox is indicated in Chagas disease but determining its effectiveness in chronic disease is hindered by the length of time needed to demonstrate negative serological conversion. We manually reviewed long-term follow-up data from hospital records of patients with chronic Chagas disease (N = 1,4...
Saved in:
Main Authors: | David Vizcaya (Author), Ulrike Grossmann (Author), Frank Kleinjung (Author), Ruiping Zhang (Author), Kiliana Suzart-Woischnik (Author), Sandra Seu (Author), Teresa Ramirez (Author), Leylen Colmegna (Author), Oscar Ledesma (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.
by: Rocio Rivero, et al.
Published: (2023) -
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
by: Miriam Rolon, et al.
Published: (2022) -
Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease.
by: Samanta Moroni, et al.
Published: (2019) -
Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
by: Jaime Altcheh, et al.
Published: (2021) -
Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
by: Fiorella Bianchi, et al.
Published: (2015)